Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up – Here’s What Happened

Shares of Rapport Therapeutics (NASDAQ:RAPP) gapped up prior to trading on Wednesday . The stock had previously closed at $12.69, but opened at $13.51. Rapport Therapeutics shares last traded at $13.76, with a volume of 11,234 shares trading hands.

Rapport Therapeutics Price Performance

The firm’s fifty day moving average price is $20.00 and its 200-day moving average price is $21.36.

Hedge Funds Weigh In On Rapport Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RAPP. ARCH Venture Management LLC acquired a new position in Rapport Therapeutics in the 2nd quarter worth $86,730,000. Perceptive Advisors LLC acquired a new position in Rapport Therapeutics in the 2nd quarter worth $17,403,000. FMR LLC boosted its stake in Rapport Therapeutics by 10.1% in the 3rd quarter. FMR LLC now owns 5,486,468 shares of the company’s stock worth $112,363,000 after purchasing an additional 503,117 shares during the period. Logos Global Management LP acquired a new position in Rapport Therapeutics in the 2nd quarter worth $4,859,000. Finally, Geode Capital Management LLC acquired a new position in Rapport Therapeutics in the 3rd quarter worth $4,133,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.